Mastering the Evolving Treatment Landscape in HER2-Positive Breast Cancer

Credits Available:

3.5 AMA PRA Category 1 Credits™, 3.5 ANCC, 3.5 ACPE

• Mastering the Evolving Treatment Landscape in HER2-Positive Breast Cancer: Baseline Assessment

  In this section, we will ask a series of questions regarding the management of HER2+ breast cancer. We will ask the questions twice: once prior to the education and then a second time after. These questions are intended to gauge the educational impact of this program.

• Self Study Module 1 - MedicalMinute: Case Discussion: Localized HER2-Positive Breast Cancer

  In this module, Dr. Claudine Isaacs discusses various neoadjuvant therapy regimens and how to optimally manage residual disease after neoadjuvant therapy and surgery.

• Self Study Module 2 - MedicalMinute: Case Discussion: HER2-Positive Metastatic Breast Cancer

  In this module, Dr. Claudine Isaacs guides the learner through treatment options for metastatic HER2-positive breast cancer.

• Self Study Module 3 - MedicalMinute: Case Discussion: HER2-Positive Breast Cancer With Brain Metastases

  In this module, Dr. Aditya Bardia describes the latest evidence on therapies that have demonstrated efficacy in targeting brain metastases, including small molecule inhibitors and antibody-drug conjugates.

• Self Study Module 4 - MedicalMinute: Future Considerations: Therapeutic Strategies on the Horizon

  In this module, Dr. Aditya Bardia discusses novel therapies, combination approaches, ongoing clinical trials to improve patient outcomes.

• Mastering the Evolving Treatment Landscape in HER2-Positive Breast Cancer: Final Assessment

  Now that you have learned more about the management of HER2+ breast cancer, we ask you to please revisit the questions you addressed at the start of this program.

• The Evolving Treatment Landscape and Unanswered Questions in HER2+ Breast Cancer

  This live discussion will focus on providing optimal care for patients with HER2+ breast cancer. Topics to be discussed include recent changes to the treatment landscape, unanswered questions in HER2+ breast cancer, and creating evidence-based, patient-specific plans for HER2+ breast cancer.

• Applying Evidence to Practice: Case Studies and Action Plans

  In this discussion, we will review case study responses and how the findings apply to improving care for patients with HER2+ breast cancer; we will also review challenges, clinical controversies, and aspects of patient treatment that should be considered. Action plans will presented as we reflect on how our practice will evolve as a result of this CME activity.

• Treatment Decisions in Early Breast Cancer: Patient Case 1 - Ms Watkins

  Meet Ms Watkins, a younger patient with ER-positive, HER2-positive breast cancer. The group objective of this segment is to explore all aspects of disease management in this patient with residual disease post neoadjuvant therapy and surgery.

• Clinical Decision-making in Advanced Disease: Patient Case 2 - Mrs Parker

  Meet Mrs Parker, an older patient with metastatic HER2-positive breast cancer that has progressed following chemotherapy. The group objective of this segment is to explore all aspects of disease management in this patient.

• Create an Action Plan

  In light of the information reviewed and discussed during this program, can you share an action plan that you will implement to improve the outcomes for your patients with HER2+ Breast Cancer.

Thank you for your interest. Currently, the curriculum is closed for enrollment but we encourage you to keep an eye out for future opportunities or alternative programs that might align with your educational goals.

View Other Offerings